查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1512044

美國大麻市場規模、佔有率和趨勢分析報告：2024-2030 年按來源、衍生物、最終用途和細分市場進行的預測

U.S. Cannabis Market Size, Share & Trends Analysis Report By Source (Hemp, Marijuana), By Derivatives (CBD, THC), By End-use (Medical Use, Recreational Use), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國大麻市場成長與趨勢：

Grand View Research, Inc.的最新報告顯示，到2030年，美國大麻市場規模預計將達到401億美元，2024年至2030年的複合年成長率為13.7%。藥用大麻合法化、消費者可支配收入增加、製藥行業對大麻的需求增加、消費者對大麻健康益處的認知提高、大型製造商的存在以及美國農業法案的核准等因素預計將提振市場成長。

大麻通常用於治療多種疾病，包括癌症、精神障礙、疼痛管理和噁心以及娛樂。癌症高發生率預計將成為預測期內推動醫用大麻採用的因素之一。例如，美國癌症協會2023年1月發表的報導估計，美國將有609,820人死於癌症，並且將有1,958,310個新病例被診斷出患有癌症。此外，兩種大麻二酚（CBD）藥物大麻隆和屈大麻酚已在美國獲得FDA核准用於治療化療引起的噁心和嘔吐。

此外，大眾對大麻治療功效的認知不斷提高，以及透過合作夥伴關係推出大麻認證計劃，正在推動市場成長。例如，2023年12月，貝拉明大學推出了肯塔基州公立大學提供的大麻教育認證計劃，重點是快速變化的大麻產業中的農業、商業、醫學和法律。

隨著美國各地醫用和娛樂大麻合法化，許多名人和主流公司都希望從這一趨勢中獲利。例如，Jay-Z 和 Snoop Dogg 等名人也加入了這項運動，推出了品牌大麻產品（字母組合）。但狂熱的大麻消費者希望了解名人參與種植過程的程度。儘管有這樣的審查，我們仍然可以預期更多的名人會追隨這一趨勢並進入大麻種植行業。

此外，大麻種植的新技術和改進也在不斷開發。隨著對技術先進的大麻生產的需求不斷增加，這些增強的技術預計將幫助種植者最佳化資源，進一步推動市場成長。

美國大麻市場報告亮點

  • 從來源來看，大麻產業在 2023 年的銷售中佔據了最大佔有率，因為用於醫療目的的大麻正在獲得認可並且其使用正在合法化。
  • 從衍生性商品來看，由於人們對含有 CBD 的食品、化妝品和藥品的接受度不斷提高，需求不斷增加，CBD 細分市場將佔據最大的收益佔有率，並在 2023 年主導市場。
  • 按最終用途分類，由於支持 CBD 在治療各種慢性疾病方面的效用的研究活動和臨床試驗的增加，醫療用途領域在 2023 年佔據了最大的收益佔有率。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章美國大麻市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 案例研究分析
  • 營商環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
  • 監管狀況

第 4 章 2018-2030 年美國大麻市場細分分析（按來源）

  • 定義和範圍
  • 源細分儀表板
  • 2018-2030年市場規模、預測及趨勢分析
  • 麻
    • 2018 年至 2030 年市場估計與預測
    • 油
    • 工業大麻
  • 大麻
    • 花
    • 油和酊劑

第5章美國大麻市場細分分析（依衍生物），2018-2030

  • 定義和範圍
  • 衍生物細分儀表板
  • 2018-2030年市場規模、預測及趨勢分析
  • CBD
    • 2018 年至 2030 年市場估計與預測
  • THC
    • 2018 年至 2030 年市場估計與預測
  • 其他
    • 2018 年至 2030 年市場估計與預測

第6章 2018-2030 年美國大麻市場細分分析（依最終用途）

  • 定義和範圍
  • 最終用途細分儀表板
  • 2018-2030年市場規模、預測及趨勢分析
  • 工業用途
    • 2018 年至 2030 年市場估計與預測
  • 醫療用途
    • 2018 年至 2030 年市場估計與預測
    • 慢性疼痛
    • 憂鬱症和焦慮
    • 關節炎
    • 創傷後壓力症候群（PTSD）
    • 癌症
    • 偏頭痛
    • 癲癇
    • 阿茲海默症
    • 多發性硬化症
    • 肌萎縮側索硬化症
    • 妥瑞症
    • 糖尿病
    • 帕金森氏症
    • 青光眼
    • 其他
  • 休閒用途
    • 2018 年至 2030 年市場估計與預測

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 公司市場分析
  • 公司簡介
    • Tilray Brands
    • Canopy Growth Corporation
    • Medical Marijuana, Inc.
    • NuLeaf Naturals, LLC
    • CV Sciences, Inc.
    • CHARLOTTE'S WEB.
    • The Cronos Group
    • Organigram Holding, Inc
    • Irwin Naturals
    • Aurora Cannabis
Product Code: GVR-2-68038-978-4

U.S. Cannabis Market Growth & Trends:

The U.S. cannabis market size is expected to reach USD 40.10 billion by 2030, registering a CAGR of 13.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Factors such as legalization of medicinal cannabis, growing consumer disposable income, rising demand for cannabis from the pharmaceutical industry, growing consumer awareness of the health benefits of cannabis, presence of major manufacturers, and the approval of the U.S. farm bill are expected to boost the market growth.

Cannabis is generally used for the treatment of various conditions, such as cancer, mental disorders, pain management, & nausea, and for recreational purposes. The high prevalence of cancer is expected to be one of the factors driving the adoption of medical marijuana over the forecast period. For instance, according to an article published by the American Cancer Society in January 2023, 609,820 cancer deaths and 1,958,310 new cancer cases were anticipated to occur in the U.S. In addition to that, two cannabidiol (CBD) drugs namely nabilone and dronabinol are approved by the FDA for the treatment of vomiting and nausea caused by chemotherapy in the U.S.

Furthermore, rising awareness among people regarding the therapeutic benefits of cannabis and the launch of cannabis certification programs through partnerships drives market growth. For instance, in December 2023, Bellarmine University introduced a cannabis education certificate program offered by a public Kentucky University focusing on agriculture, business, medicine, and law in the fast-changing cannabis industry.

With the legalization of cannabis in different areas of the U.S. for medical & recreational use, many well-known personalities and mainstream companies are seeking to benefit from this trend. For instance, celebrities such as Jay-Z and Snoop Dogg have joined this movement by launching branded cannabis products (Monogram). However, avid cannabis consumers seek information regarding the extent of the celebrity's involvement in the cultivation process. Despite this scrutiny, more celebrities are expected to follow this trend and enter the cannabis cultivation industry.

Moreover, new technologies and improvements are continually being developed for the cultivation of cannabis. With an increasing demand for technologically advanced cannabis production, these expanded techniques are anticipated to assist cultivators in optimizing their resources, which further drives the market growth.

U.S. Cannabis Market Report Highlights:

  • Based on source, the marijuana segment accounted for the largest revenue share in 2023 due to the recognition of cannabis for medical purposes and the increasing legalization of its use
  • Based on derivative, the CBD segment dominated the market with the largest revenue share in 2023, owing to growing acceptance and a rise in demand for CBD-infused food, cosmetics, and medication
  • Based on end-use, the medical use segment held the largest revenue share in 2023 due to the increasing research activity and growing clinical trials supporting its benefits in treating various chronic diseases

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Source
    • 1.2.2. Derivatives
    • 1.2.3. End-use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
    • 2.2.1. Source outlook
    • 2.2.2. Derivatives outlook
    • 2.2.3. End-use outlook
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Cannabis Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing adoption of medical marijuana for treatment of chronic diseases
      • 3.2.1.2. Impending legalization of marijuana for recreational/adult use
      • 3.2.1.3. Rising number of research studies on cannabis for various ailments
      • 3.2.1.4. Growing legalization and awareness of cannabis in various states in the U.S.
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of cannabis and CBD-based products
      • 3.2.2.2. lack of consistency in advertising policies regarding cannabis
    • 3.2.3. Case Study Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis
  • 3.4. Regulatory Landscape

Chapter 4. U.S. Cannabis Market Segment Analysis, By Source, 2018 - 2030 (USD Million)

  • 4.1. Definition and Scope
  • 4.2. Source Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4. Hemp
    • 4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Hemp oil
      • 4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Industrial Hemp
      • 4.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Marijuana
      • 4.5.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.5.2. Flower
      • 4.5.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.5.3. Oil and Tinctures
      • 4.5.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Cannabis Market Segment Analysis, By Derivative, 2018 - 2030 (USD Million)

  • 5.1. Definition and Scope
  • 5.2. Derivatives Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4. CBD
    • 5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. THC
    • 5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. U.S. Cannabis Market Segment Analysis, By End-use, 2018 - 2030 (USD Million)

  • 6.1. Definition and Scope
  • 6.2. End-use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4. Industrial Use
    • 6.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Medical Use
    • 6.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.2. Chronic Pain
      • 6.5.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.3. Depression and Anxiety
      • 6.5.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.4. Arthritis
      • 6.5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.5. Post Traumatic Stress Disorder (PTSD)
      • 6.5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.6. Cancer
      • 6.5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.7. Migraines
      • 6.5.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.8. Epilepsy
      • 6.5.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.9. Alzheimer's Disease
      • 6.5.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.10. Multiple Sclerosis
      • 6.5.10.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.11. Amyotrophic Lateral Sclerosis
      • 6.5.11.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.12. Tourette's Syndrome
      • 6.5.12.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.13. Diabetes
      • 6.5.13.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.14. Parkinson's Disease
      • 6.5.14.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.15. Glaucoma
      • 6.5.15.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.5.16. Others
      • 6.5.16.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Recreational Use
    • 6.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Market Position Analysis
  • 7.4. Company Profiles
    • 7.4.1. Tilray Brands
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Service Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Canopy Growth Corporation
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Service Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Medical Marijuana, Inc.
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Service Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. NuLeaf Naturals, LLC
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Service Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. CV Sciences, Inc.
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Service Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. CHARLOTTE'S WEB.
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Service Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. The Cronos Group
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Service Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Organigram Holding, Inc
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Service Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Irwin Naturals
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Service Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Aurora Cannabis
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Service Benchmarking
      • 7.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. cannabis market, by source, 2018 - 2030 (USD Million)
  • Table 4 U.S. cannabis market, by derivatives, 2018 - 2030 (USD Million)
  • Table 5 U.S. cannabis market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Value-chain-based sizing & forecasting
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market research approaches
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. cannabis market: market outlook
  • Fig. 9 U.S. cannabis competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook.
  • Fig. 12 Industry value chain analysis
  • Fig. 13 U.S. cannabis market driver impact
  • Fig. 14 U.S. cannabis market restraint impact
  • Fig. 15 U.S. cannabis market strategic initiatives analysis
  • Fig. 16 U.S. cannabis market: Source movement analysis
  • Fig. 17 U.S. cannabis market: Source outlook and key takeaways
  • Fig. 18 Hemp market estimates and forecasts, 2018 - 2030
  • Fig. 19 Hemp Oil market estimates and forecasts, 2018 - 2030
  • Fig. 20 Industrial Hemp market estimates and forecasts, 2018 - 2030
  • Fig. 21 Marijuana market estimates and forecasts, 2018 - 2030
  • Fig. 22 Flower market estimates and forecasts, 2018 - 2030
  • Fig. 23 Oil and Tinctures market estimates and forecasts, 2018 - 2030
  • Fig. 24 U.S. cannabis market: Derivatives movement analysis
  • Fig. 25 U.S. cannabis market: Derivatives outlook and key takeaways
  • Fig. 26 CBD market estimates and forecasts, 2018 - 2030
  • Fig. 27 THC market estimates and forecasts, 2018 - 2030
  • Fig. 28 Others market estimates and forecasts, 2018 - 2030
  • Fig. 29 U.S. cannabis market: End-use movement analysis
  • Fig. 30 U.S. cannabis market: End-use outlook and key takeaways
  • Fig. 31 Industrial Use market estimates and forecasts, 2018 - 2030
  • Fig. 32 Medical Use market estimates and forecasts, 2018 - 2030
  • Fig. 33 Chronic Pain market estimates and forecasts, 2018 - 2030
  • Fig. 34 Depression and Anxiety market estimates and forecasts, 2018 - 2030
  • Fig. 35 Arthritis market estimates and forecasts, 2018 - 2030
  • Fig. 36 Post Traumatic Stress Disorder (PTSD) market estimates and forecasts, 2018 - 2030
  • Fig. 37 Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 38 Migraines market estimates and forecasts, 2018 - 2030
  • Fig. 39 Epilepsy market estimates and forecasts, 2018 - 2030
  • Fig. 40 Alzheimer's market estimates and forecasts, 2018 - 2030
  • Fig. 41 Multiple Sclerosis market estimates and forecasts, 2018 - 2030
  • Fig. 42 AIDS market estimates and forecasts, 2018 - 2030
  • Fig. 43 Amyotrophic Lateral Sclerosis market estimates and forecasts, 2018 - 2030
  • Fig. 44 Tourette's market estimates and forecasts, 2018 - 2030
  • Fig. 45 Diabetes market estimates and forecasts, 2018 - 2030
  • Fig. 46 Parkinson's market estimates and forecasts, 2018 - 2030
  • Fig. 47 Glaucoma market estimates and forecasts, 2018 - 2030
  • Fig. 48 Others market estimates and forecasts, 2018 - 2030
  • Fig. 49 Recreational Use market estimates and forecasts, 2018 - 2030
  • Fig. 50 Key company categorization